Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments
Despite New VC Cash, Company Fundraising Sank In Q1
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
You may also be interested in...
Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Forbion Will Use New Fund To Rescue Struggling Biotechs
The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.
Finance Watch: New Funds Keep Venture Capital Flowing Into Biopharma
Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round.